Well Biocon is a partner so you are wrong first thing ,selling in EU countries and making money while getting FDA tests done is very unique , Management IQ is very high not suspect, A rs in some cases is a very good move to get to the big boards with institutional investors that have been pounding on Cytosorbents door ,311 million is average for this much potential. And yes a company must build out with increase sales that is just business 101 . I can see why you are getting Hammered .
News 
Market Data 
Discover 
